Opinion

Video

Overview and Benefits of Port Delivery System with Ranibizumab

Author(s):

Aleksandra Rachitskaya, MD,Jordan Graff, MD, FACS

Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that provides continuous medication delivery for 6 months, offering patients a preferred alternative to frequent intravitreal injections while ensuring consistent therapeutic levels.

Video content above is prompted by the following:

  • Can you provide an overview of the port delivery device with ranibizumab approved for treating neovascular AMD?
  • How does the device function?
  • What are the benefits of using the port delivery device with ranibizumab?
  • Certainty of 6 months of continuous anti-VEGF delivery
  • Patients in clinical trials prefer PDS over intravitreal injections

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
Related Content
(Image credit: Wilmer Eye Institute/Johns Hopkins Medicine)
June 27th 2025

Wilmer Eye Institute marks 100 years: honoring the past, shaping the future

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image courtesy of New York Eye and Ear Infirmary of Mount Sinai) Q&A: Kira Manusis, MD, on how the Center for Refractive Solutions is redefining patient care at NYEE
June 23rd 2025

Q&A: Kira Manusis, MD, on how the Center for Refractive Solutions is redefining patient care at NYEE

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

(Image credit: AdobeStock/peopleimages.com) Rethinking end points in AMD: the power of OCT imaging with Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS
June 18th 2025

Rethinking end points in AMD: the power of OCT imaging with Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS

(Image credit: AdobeStock/Sam Efendi) Analyzing FLIO data from the AI-READI project with Aaron Y. Lee, MD, MSCI
June 17th 2025

Analyzing FLIO data from the AI-READI project with Aaron Y. Lee, MD, MSCI

© 2025 MJH Life Sciences

All rights reserved.